NASDAQ: ZGNX

Corporate Update

Leerink Global
Healthcare Conference
February 2017
Forward Looking Statement

Zogenix cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements.
Words such as "believes," "anticipates," "plans," "expects," "indicates," "will," "intends," "potential," "suggests," "assuming," "designed" and
similar expressions are intended to identify forward-looking statements. These statements are based on the company's current beliefs and
expectations. These forward-looking statements include statements regarding the potential commercialization of ZX008; the timing of the
completion of the Phase 3 clinical trials of ZX008 in Dravet syndrome and other 2017 and 2018 milestones; Zogenixs financial position and
potential cash runway without the need to raise additional capital; and the timing of any submission of an investigational new drug application to
the U.S. Food and Drug Administration. The inclusion of forward-looking statements should not be regarded as a representation by Zogenix that
any of its plans will be achieved. Actual results may differ from those set forth in this release due to the risks and uncertainties inherent in
Zogenix's business, including, without limitation: the uncertainties associated with the clinical development and regulatory approval of product
candidates such as ZX008, including potential delays in the commencement, enrollment and completion of clinical trials; the potential that earlier
clinical trials and studies may not be predictive of future results; Zogenix's reliance on third parties to conduct its clinical trials, enroll patients,
manufacture its preclinical and clinical drug supplies and manufacture commercial supplies of its drug products, if approved; unexpected adverse
side effects or inadequate therapeutic efficacy of ZX008 that could limit approval and/or commercialization, or that could result in recalls or
product liability claims; Zogenix's ability to fully comply with numerous federal, state and local laws and regulatory requirements, as well as rules
and regulations outside the United States, that apply to its product development activities; Fast Track designation may not result in an expedited
regulatory review process; Zogenixs cash burn rate may be greater than anticipated; the potential for distraction of management related to the
transition of management responsibilities; and other risks described in Zogenix's prior press releases as well as in public periodic filings with the
Securities and Exchange Commission.

You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and Zogenix
undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof. All forward-looking
statements are qualified in their entirety by this cautionary statement.

2
ZX008 Dravet Syndrome Global
Phase 3 Program
ZX008 as adjunctive treatment for seizures in children and
young adults with Dravet syndrome

Study 1501(1) /Study 1502(2) Study 1504(3)

Double-blind, randomized, placebo- Double-blind, randomized, placebo-

controlled, 12-week treatment controlled, 12-week treatment

Standard of care; Standard of care;

Stiripentol excluded All patients on stiripentol

Primary outcome: Change from Primary outcome: Change from

baseline in frequency of convulsive baseline in frequency of convulsive
seizures seizures

FDA confirmation of adequate and FDA confirmation of adequate and

well-controlled pivotal study design well-controlled pivotal study design

(1) North American clinical sites (3) European and North American clinical sites
(2) European/Australian clinical sites
3
ZX008 Dravet Syndrome Phase 3 Status

Over 160 patients enrolled

Full recruitment of Studies 1501 and 1502 taking longer than

anticipated; best-case completion now projected 2018

Studies 1501 and 1502 may not fully enroll as independent trials

Merging of enrolled subjects in Studies 1501 and 1502 enables pivotal

study readout (Study 1)

Study 1504 may serve as second pivotal study

4
ZX008 Phase 3 Strategy in Dravet Syndrome
2016 2017 2018

1501

1502

Study 1 top-line
(n=120)
PIVOTAL #1

1504 top-line
1504
PIVOTAL #2

5
Other Highlights

ZX008
Exclusivity Method of use patents issued for ZX008; 2033 expiry

Lennox Successful Pre-IND meeting; IND submission Q1 2017

Gastaut
Syndrome Phase 3 initiation for ZX008 in H2 2017

Business & Funds to support operations into Q2 2018

Financial No plans to raise capital ahead of Phase 3 data

6
 Phase 3 data in 2017
Study 1504 may serve as second
pivotal study

Strong cash position; no plans to

raise capital prior to Phase 3 data